TC BioPharm reports progress in AML treatment trial
PLC (NASDAQ: TCBP), a biotechnology firm with a market capitalization of $33.08 million engaged in developing gamma-delta T cell therapies, announced today significant progress in its ACHIEVE Phase 2B ...
Malaysian Reserve13 小时
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy ...
The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...
Le Lézard17 小时
CARsgen's First Enrolled Subject in the THANK-u Plustm Platform-Based Allogeneic CAR-T ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...
Malaysian Reserve17 小时
CARsgen’s First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies ...